by synergycap1 | Jul 27, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
Vehicles can track phone calls and texts, and log queries to websites. Who gets what information and for what purposes? This is what you should know.
by synergycap1 | Jul 27, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Finance, Non-Bank Loans, Working Capital
Less than a year from now, the General Data Protection Regulation (GDPR) goes into effect. This week, New York City-based Evidon launched a beta version of which it says is “the first practical, commercial-grade solution” to collect user permissions in...
by synergycap1 | Jul 27, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
Facebook’s co-founder and chief executive, Mark Zuckerberg, looks like he has the next five years planned out, and as a result shares of the social network are cheap, CNBC’s Jim Cramer said Thursday. Facebook stock was up about 5 percent Thursday morning...
by synergycap1 | Jul 27, 2017 | Bad Credit Loans, Bank Lending, Business Loans, Capital, Non-Bank Loans, Working Capital
I spend very little time writing copy myself these days because I’m too busy running an agency. I had to learn all that marketing and branding stuff because it was necessary to grow Tailored Ink and serve my clients better, too. Related: 5 Copywriting...
by synergycap1 | Jul 27, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
[The stream is slated to start at 10 a.m., ET. Please refresh the page if you do not see a player above at that time.] Randal Quarles, a nominee to the Federal Reserve Board of Governors, goes before the Senate Banking Committee on Thursday. President Donald Trump has...
by synergycap1 | Jul 27, 2017 | Bad Credit Loans, Business Lending, Business Loans, Capital, Finance, Non-Bank Loans, Working Capital
Chasing exciting new developments in medicine can be a very expensive endeavor. Such is the takeaway from AstraZeneca’s announcement that a hotly anticipated clinical trial didn’t meet expectations.
